Prognostic variables in node-negative and node-positive breast cancer โ{128}{148} Introduction -- Routinely available indicators of prognosis in breast cancer -- Prognostic factors for patients with breast cancers 1cm and smaller -- Steroid hormone receptors in breast cancer management -- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer -- S-phase fraction and breast cancer โ{128}{148} a decade of experience -- Prognostic and predictive value of thymidine labelling index in breast cancer -- Cyclin D1 in breast cancer -- Cyclins and breast cancer -- Prognostic implications of expression of the cell cycle inhibitor p27Kip1 -- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer -- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients -- HER-2/neu as a predictive marker of response to breast cancer therapy -- Prognostic and predictive value of p53 and p21 in breast cancer -- The urokinase plasminogen activator system as a target for prognostic studies in breast cancer -- Metalloproteinases and tissue inhibitors of metalloproteinases -- Matrix metalloproteinase inhibitors -- The 67 kDa laminin receptor as a prognostic factor in human cancer -- Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis -- Clinical significance of angiogenic factors in breast cancer -- Insulin-like growth factors in human breast cancer -- Molecular prognostic markers in breast cancer -- Prognostic significance of micrometastatic bone marrow involvement -- Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis -- Time-dependence of hazard ratios for prognostic factors in primary breast cancer -- Circulating tumor markers in breast cancer: Accepted utilities and novel prospects -- The relationship between prognostic and predictive factors in the management of breast cancer -- Methodological challenges in the evaluation of prognostic factors in breast cancer -- Assessing the clinical impact of prognostic factors: When is โ{128}{156}statistically significantโ{128}{157} clinically useful? -- Prognostic variables in node-negative and node-positive breast cancer โ{128}{148} editorial -- Author index